Diabetic Retinopathy Market to Register Incremental Growth by 2032, Asserts DelveInsight | Leading Companies in the Market - Opthea, Regenxbio, Kodiak, Ocuphire, Eisai, Apexian, Oculis, Bayer, Novartis, Allegro

The diabetic retinopathy market dynamics are anticipated to change in the coming years owing to the extensive research and development activities of pharmaceutical companies, along with the launch of various multiple-stage pipeline products.

New York, USA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- *Diabetic Retinopathy Market to Register Incremental Growth by 2032, Asserts DelveInsight | Leading Companies in the Market - Opthea, Regenxbio, Kodiak, Ocuphire, Eisai, Apexian, Oculis, Bayer, Novartis, Allegro *

*The diabetic retinopathy market dynamics are anticipated to change in the coming years owing to the extensive research and development activities of pharmaceutical companies, along with the launch of various multiple-stage pipeline products.*

DelveInsight’s *Diabetic Retinopathy Market Insights* report includes a comprehensive understanding of current treatment practices, diabetic retinopathy emerging drugs, market share of individual therapies, and current and forecasted diabetic retinopathy market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

*Key Takeaways from the Diabetic Retinopathy Market Report*

· As per DelveInsight’s analysis, the diabetic retinopathy market is anticipated to grow at a significant CAGR by 2032.
· As per DelveInsight estimates, the total 7MM prevalent cases of diabetic retinopathy were *12.5 million* in 2021.   
· Leading diabetic retinopathy companies such as *Opthea Limited, Regenxbio, Kodiak Sciences Inc., Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd., Roche, *and others are developing novel diabetic retinopathy drugs that can be available in the diabetic retinopathy market in the coming years.
· Some of the key therapies for diabetic retinopathy treatment include *OPT-302, RGX 314, KSI-301, APX3330, OCS-01, Runcaciguat (BAY 1101042), Brolucizumab, LKA651, Risuteganib, ADVM-022, GB-102, Emixustat Hydrochloride, KVD001, RG7774**, *and others. 

Discover which therapies are expected to grab the major diabetic retinopathy market share @ *Diabetic Retinopathy Market Report*

*Diabetic Retinopathy Overview*

Diabetic retinopathy, a microvascular disorder, is a consequence of prolonged diabetes, resulting in vision-threatening damage to the retina and, ultimately, blindness. This condition can affect individuals with either diagnosed or undiagnosed diabetes mellitus. The likelihood of developing diabetic retinopathy is directly linked to the patient's age, duration of diabetes, and the quality of glycemic control, as well as fluctuations in blood pressure levels. During its early stages, many individuals may not experience any noticeable diabetic retinopathy symptoms. However, as the condition progresses, symptoms such as blurred or distorted vision, new color blindness, night blindness, the presence of eye floaters or streaks in vision, and difficulty reading or seeing distant objects may become apparent. The diagnosis of diabetic retinopathy is established through a comprehensive dilated eye examination, which may also involve specialized diagnostic tests such as fluorescein angiography and optical coherence tomography to assess abnormalities in both the internal and external structures of the eyes.

*Diabetic Retinopathy Epidemiology Segmentation*

The diabetic retinopathy epidemiology section provides insights into the historical and current diabetic retinopathy patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The *diabetic retinopathy market report* proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

· Total Diabetic Retinopathy Prevalent Cases
· Diabetic Retinopathy Gender-Specific Prevalent Cases
· Diabetic Retinopathy Severity-Specific Prevalent Cases 
· Diabetic Retinopathy Age-Specific Prevalent Cases

Download the report to understand which factors are driving diabetic retinopathy epidemiology trends @ *Diabetic Retinopathy Epidemiological Insights*

*Diabetic Retinopathy Treatment Market *

Current treatments for diabetic retinopathy are quite limited, with a strong emphasis on addressing macular edema. In the past, conventional therapies like vitrectomy, photocoagulation, and corticosteroids were the go-to options. However, they offered no potential for vision improvement and carried a high risk of complications. Conversely, anti-vascular endothelial growth factor (anti-VEGF) medications have made significant strides in helping those with diabetic macular edema (DME) in the past decade. 

Nevertheless, even these medications do not yield consistent success for all patients, particularly those in the advanced stages of the disease. The primary choice for initial therapy typically revolves around three anti-VEGF drugs. These drugs work by inhibiting the development of new blood vessels and reducing swelling in the macula, thus slowing down the progression of vision loss and potentially enhancing eyesight. These agents are administered through eye injections and encompass aflibercept (marketed as *EYLEA by Regeneron and Bayer), ranibizumab (known as LUCENTIS, developed by Genentech and Novartis), and bevacizumab (commercialized as AVASTIN by Genentech)*. Collectively, these medications dominate the diabetic retinopathy treatment landscape.

LUCENTIS was the pioneering anti-VEGF medication to demonstrate long-lasting improvements in maintaining vision. Presently, Eylea has become the widely accepted standard of care and the leading drug in nearly all retinal disorders. Its usage has seen substantial growth, especially in the diabetic macular edema market, thanks to studies indicating its potential superiority over other options for DME patients with more advanced conditions.

Learn more about the FDA-approved drugs for diabetic retinopathy @ *Drugs for* *Diabetic Retinopathy** Treatment*

*Key Diabetic Retinopathy Therapies and Companies*

· OPT-302: Opthea Limited
· RGX 314: Regenxbio
· KSI-301: Kodiak Sciences Inc.
· APX3330: Ocuphire Pharma/Eisai Co Ltd/Apexian Pharmaceuticals
· OCS-01: Oculis
· Runcaciguat (BAY 1101042): Bayer
· Brolucizumab: Novartis Pharmaceuticals
· LKA651: Novartis Pharmaceuticals
· Risuteganib: Allegro Ophthalmics, LLC
· ADVM-022: Adverum Biotechnologies, Inc.
· GB-102: Graybug Vision
· Emixustat Hydrochloride: Kubota Vision Inc.
· KVD001: KalVista Pharmaceuticals Ltd.
· RG7774: Roche

To know more about diabetic retinopathy clinical trials, visit @ *Diabetic Retinopathy Treatment Drugs*

*Diabetic Retinopathy Market Dynamics*

The dynamics of the diabetic retinopathy market are expected to change in the coming years. Various pathways have been thoroughly investigated as potential causes of the disease, leading to a *deeper understanding* after years of research and development. The presence of a substantial patient population enables companies to develop* cost-effective drugs* and achieve significant profits.

Furthermore, potential therapies are being investigated for the treatment of diabetic retinopathy, and it is safe to predict that the treatment space will significantly impact the diabetic retinopathy market during the forecast period. Moreover, the *anticipated introduction of emerging therapies* with improved efficacy and a further *improvement in the diagnosis rate* are expected to drive the growth of the diabetic retinopathy market in the 7MM.

However, several factors are impeding the growth of the diabetic retinopathy market. The *absence of biomarkers* to guide treatment planning for individuals with diabetic retinopathy is a significant challenge. Moreover, the *imminent expiration of patents* for popular drugs such as *Aflibercept and Ranibizumab*, along with the impending release of biosimilars by various companies, could pose a substantial obstacle.

Furthermore, the diabetic retinopathy market growth may be offset by *failures and discontinuation of emerging therapies*, *unaffordable pricing*, *market access and reimbursement issues*, and a *shortage of healthcare specialists*. In addition, the *undiagnosed, unreported cases and the unawareness* about the disease may also impact the diabetic retinopathy market growth.

*Diabetic Retinopathy Report Metrics* *Details*
Study Period 2019–2032
Diabetic Retinopathy Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Diabetic Retinopathy Companies Opthea Limited, Regenxbio, Kodiak Sciences Inc., Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd., Roche, and others
Key Diabetic Retinopathy Therapies OPT-302, RGX 314, KSI-301, APX3330, OCS-01, Runcaciguat (BAY 1101042), Brolucizumab, LKA651, Risuteganib, ADVM-022, GB-102, Emixustat Hydrochloride, KVD001, RG7774, and others

*Scope of the **Diabetic Retinopathy** Market Report*

· *Therapeutic Assessment: *Diabetic Retinopathy current marketed and emerging therapies
· *Diabetic Retinopathy* *Market Dynamics:* Attribute Analysis of Emerging Diabetic Retinopathy Drugs
· *Competitive Intelligence Analysis:* SWOT analysis and Market entry strategies
· *Unmet Needs, KOL’s views, Analyst’s views, Diabetic Retinopathy Market Access and Reimbursement*

Discover more about diabetic retinopathy drugs in development @ *Diabetic Retinopathy Clinical Trials*

*Table of Contents*

1. Diabetic Retinopathy Market Key Insights
2. Diabetic Retinopathy Market Report Introduction
3. Diabetic Retinopathy Market Overview at a Glance
4. Diabetic Retinopathy Market Executive Summary
5. Disease Background and Overview
6. Diabetic Retinopathy Treatment and Management
7. Diabetic Retinopathy Epidemiology and Patient Population
8. Patient Journey
9. Diabetic Retinopathy Marketed Drugs
10. Diabetic Retinopathy Emerging Drugs
11. Seven Major Diabetic Retinopathy Market Analysis
12. Diabetic Retinopathy Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Related Reports*

*Diabetic Retinopathy Epidemiology Forecast*

*Diabetic Retinopathy Epidemiology Forecast – 2032* report delivers an in-depth understanding of the disease, historical and forecasted diabetic retinopathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

*Diabetic Retinopathy Pipeline*

*Diabetic Retinopathy Pipeline Insight **– 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic retinopathy companies, including *Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, Palatin Technologies, Valo Health, EyePoint Pharmaceuticals, Kubota Vision, MingSight Pharmaceuticals, Oxurion, Aerie Pharmaceuticals,  AsclepiX Therapeutics, Ocugen, Ashvattha Therapeutics, Stealth BioTherapeutics,  *among others.

*Proliferative Diabetic Retinopathy Pipeline*

*Proliferative Diabetic Retinopathy Pipeline Insight – 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key proliferative diabetic retinopathy companies, including *Kubota Vision, *among others.

*Diabetic Neuropathy Pipeline*

*Diabetic Neuropathy Pipeline Insight – 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic neuropathy companies, including *Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical, *among others.

*Diabetic Neuropathy Market*

*Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast – 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetic neuropathy companies, including *Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical, *among others.

*Other Trending Reports*

*Digestive System Fistula Market** | **Dementia With Diabetes Market** | **Leber's Hereditary Optic Neuropathy Market** | **Pecoma Market** | **Adamantinoma Market** | **Pegfilgrastim Biosimilar Insight** | **Functional Constipation Market** | **DDR Defective Tumors Market** | **Nephrotic Syndrome Pipeline** | **Pelizaeus-Merzbacher Disease Market** | **Hepatic Impairment Market** | **Primary Ciliary Dyskinesia Market** | **Surgical Bleeding Market** | Radiotherapy-Induced** Oral Mucositis Market** | **Relapsed Chronic Lymphocytic Leukemia CLL Market** | **Galactosemia Market** | **Glabellar Lines Market** | **Homozygous Familial Hypercholesterolemia Market** | **HR Positive/ HER2 Negative Breast Cancer Market** | **Lebers Hereditary Optic Neuropathy LHON Market** | **Nonalcoholic Fatty Liver Disease NAFLD Market** | **Orthotic Devices Market** | **Polypoidal Choroidal Vasculopathy Market** | **Sporadic Inclusion Body Myositis Market** | **Acid Sphingomyelinase Deficiency ASMD Market** | **B-Cell Chronic Lymphocytic Leukemia Market** | **Coccidioidomycosis Market** | **Frontotemporal Dementia Pipeline** | **Granulomatosis With Polyangiitis Market** | **Malignant Pleural Mesothelioma Market** | **Nocturnal Enuresis Market** | **Postmyocardial Infarction Syndrome Market** | **Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market** | **Typhoid Fever Market** | **Ventricular Dysfunction Market** | **Burkitt Lymphoma Market** | **Chronic Progressive Multiple Sclerosis Market** | **Emesis Market** | **Fenebrutinib Market** | **Gastric Neuroendocrine Tumors Market** | **Juvenile Rheumatoid Arthritis Market** | **Persistent Epithelial Defects Market** | **Post-Polycythemia Vera Myelofibrosis Market** | **Primary Mediastinal Large B-Cell Lymphoma Market** | **Spinocerebellar Ataxias Market** | **Systemic Inflammatory Response Syndrome Market** | **Triple Negative Breast Cancer Market** | **Visceral Pain Associated With GI Disorders Market** | **Adrenal Cortex Neoplasms Market** | **Adrenal Insufficiency Market** | **Artificial Lung Devices Market** | **Atopic Keratoconjunctivitis AKC Market** | **Autonomic Dysfunction Market** | **Bradycardia Treatment Devices Market** | **Bullous Pemphigoid Market** | **Cone Rod Dystrophy Market** | **Cutaneous Lupus Erythematosus Market** | **Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market** | **Dermal Regeneration Matrix Market** | **Heart Pump Devices Market** | **Hemiplegia Market** | **Hepatic Impairement Market** | **Immunologic Deficiency Syndrome Market** | **Implantable Infusion Pump Market** | **Menorrhalgia Market Size** | **Myocarditis Market** | **Myopia Treatment Devices Market** | **Ocular Hypertension Market *

*Related Healthcare Services*

*Healthcare Consulting*

*Healthcare Competitive Intelligence Services*

*Healthcare Asset Prioritization Services*

*About DelveInsight*

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve*.*

*Connect with us on* *LinkedIn**|**Facebook**|**Twitter*

CONTACT: Contact Us

Shruti Thakur 

info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com